Solid Biosciences (SLDB) Accumulated Expenses: 2017-2024
Historic Accumulated Expenses for Solid Biosciences (SLDB) over the last 7 years, with Sep 2024 value amounting to $13.2 million.
- Solid Biosciences' Accumulated Expenses rose 15.36% to $13.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $13.2 million, marking a year-over-year increase of 15.36%. This contributed to the annual value of $10.2 million for FY2023, which is 39.12% down from last year.
- Per Solid Biosciences' latest filing, its Accumulated Expenses stood at $13.2 million for Q3 2024, which was up 33.36% from $9.9 million recorded in Q2 2024.
- In the past 5 years, Solid Biosciences' Accumulated Expenses registered a high of $16.7 million during Q4 2022, and its lowest value of $6.8 million during Q1 2021.
- Over the past 3 years, Solid Biosciences' median Accumulated Expenses value was $10.5 million (recorded in 2023), while the average stood at $11.9 million.
- In the last 5 years, Solid Biosciences' Accumulated Expenses surged by 109.24% in 2022 and then slumped by 39.12% in 2023.
- Over the past 5 years, Solid Biosciences' Accumulated Expenses (Quarterly) stood at $8.6 million in 2020, then climbed by 10.28% to $9.5 million in 2021, then spiked by 75.18% to $16.7 million in 2022, then tumbled by 39.12% to $10.2 million in 2023, then rose by 15.36% to $13.2 million in 2024.
- Its Accumulated Expenses stands at $13.2 million for Q3 2024, versus $9.9 million for Q2 2024 and $10.3 million for Q1 2024.